Company

Pfizer (IRSH)

Blog posts

Thoughts on AstraZeneca

Shareholders in AstraZeneca are no doubt pleasantly surprised by the uplift in the share price following the offers from Pfizer. The share price has doubled in the last year on improving prospects with an even sharper increase in the last few weeks as soon as a bid was rumoured. That puts the company on a historic p/e of about 20 at the time of writing. AstraZeneca has of course been a dog for some years with falling revenue and earnings, a poor ...

Become a free Associate ShareSoc member

Enter your email to sign up as a free Associate ShareSoc member and receive our emails. It takes a few seconds — and on the next page you'll have the option to customise your membership.